article thumbnail

Global Healthcare Industry – M&A and Capital Market Landscape Update

Evalueserve

On the other hand, Biotech heavily underperformed post Q1’21 primarily due to the shifting of focus towards cyclicals and negative sentiments arising as of result of greater regulatory clampdown on transformative deals and drug pricing. Sponsor deals rebounded exceptionally.

Capital 98
article thumbnail

Engage3 Team

Engage3

He has a wealth of cross-industry experience in accelerating companies’ growth and raising capital, having spent more than fifteen years in SaaS companies as CFO and COO in industries as varied as manufacturing and biotech. Kevin also has earned a CSM from Scrum Alliance and a PMC-I from Pragmatic Marketing. He holds B.A.

Retail 52